Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH)	Gossamer Bio	Ongoing	Seralutinib	3	GB002-3101	King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh)
Long-term Follow-up of Patients with Spinal Muscular Atrophy Treated with OAV101 IT or OAV101 IV in Clinical Trials	Novartis	Ongoing	OAV101 (formerly AVXS-101)	3	COAV101A12308	King Faisal Specialist Hospital and Research Center (Riyadh)
Brightline-2: A Phase IIa/IIb, open-label, single-arm, multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced / metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours	Boehringer Ingelheim Middle East & North Africa (Scientific Office) FZ Limited	Ongoing	BI 907828/ brigimadlin	2	1403-0011	King Abdulaziz Medical City NG (Riyadh)
Evaluating the efficacy and safety of Brentuximab Vedotin + AVD (Adriamycin, Vinblastine & Dacarbazine) in Newly Diagnosed Advanced Hodgkin Lymphoma Early Interim PET-Positive Patients; A Multi-Center, Open Label, Single Arm, Phase II, PET-Adaptive Study	King Abdullah International Medical Research Center (KAIMRC)	Rejected	BRENTUXIMAB VEDOTIN	3	RJ19/119/J	King Abdulaziz Medical City NG (Riyadh)
Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator’s Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide	Janssen-Cilag International NV	Ongoing	Talquetamab	3	80202135EBF3001	King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh)
The effect of novel D3 use as a mouthwash in COVID-19 patients	King Faisal Specialist Hospital & Research Centre Jeddah, Saudi Arabia	Ongoing	Cholecalciferol (vitamin D)	3	2022-32	King Faisal Specialist Hospital and Research Center (Jeddah)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants with Resistant Hypertension	Astrazeneca	Ongoing	Baxdrostat	3	D6970C00009	King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh)
A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO  TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER	Roche	Ongoing	Giredestrant , Phesgo	3	WO43571	King Abdulaziz Medical City NG (Riyadh) , King Fahad Medical City (Riyadh),King Faisal Specialist Hospital and Research Center (Riyadh)
Modified Quadruple Therapy Regimen for Helicobacter pylori Eradication – A Prospective Randomized Controlled Trial	King Faisal Specialist Hospital & Research Centre Riyadh, Saudi Arabia	Ongoing	Bismuth Subcitrate Potassium , Tetracycline , Metronidazol	2	2231295	King Faisal Specialist Hospital and Research Center (Riyadh)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Evaluate the Efficacy and Safety of RZ358 in Patients with Congenital Hyperinsulinism	Rezolute Inc	Ongoing	RZ358	3	RZ358-301	King Abdulaziz Medical City NG (Riyadh)